Trazodone - Revision history

MDElliottMD: parser-claude: Trazodone MedTemplate refill, Top 300 stub upgrade

2026-05-23T06:26:56Z

parser-claude: Trazodone MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 06:26, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Trazodone		\| generic = Trazodone
	\| brand = Desyrel		\| brand = Desyrel (original IR), Oleptro (ER), Trittico
	\| structure =		\| structure =
	\| classes = SARI, Antidepressant, ~~Sedative-Hypnotic~~		\| classes = [[:Category:SARIs\|Serotonin antagonist and reuptake inhibitor (SARI)]], [[:Category:Antidepressants\|Antidepressant]], [[:Category:Sleep aids\|Sleep aid]]
	\| ~~mechanism~~ = ~~Serotonin reuptake inhibitor and 5~~-~~HT2A antagonist~~		\| uses = <vote slug="major-depressive-disorder-use">Major depressive disorder (FDA, original indication)</vote>, <vote slug="insomnia-trazodone-use">Insomnia (off-label; vastly more common in current practice than the depression indication)</vote>, <vote slug="anxiety-adjunct-use">Anxiety disorder adjunct (off-label)</vote>, <vote slug="ptsd-sleep-disturbance-use">PTSD-related sleep disturbance (off-label)</vote>
	\| ~~uses~~ =		\| starting_dose = Insomnia (off-label): 25-50 mg PO at bedtime, titrate to effect. Depression: 150 mg/day divided BID-TID; titrate to 400 mg/day outpatient or 600 mg/day inpatient
	\| ~~starting_dose~~ =		\| preparations = IR tablets 50, 100, 150, 300 mg; Oleptro ER tablets 150, 300 mg
	\| ~~preparations~~ =		\| fda_max = 400 mg/day outpatient; 600 mg/day inpatient
	\| ~~fda_max~~ =		\| pill_id =
	\| routes =		\| routes = Oral
	\| onset =		\| onset = Sleep effect within 30-60 minutes; antidepressant effect over 1-2 weeks
	\| duration =		\| duration = ~6-8 hours (IR); 24 hours (Oleptro ER)
	\| halflife =		\| halflife = Biphasic: ~3-6 hours alpha, ~5-9 hours beta<ref name="trazodone-label">FDA Prescribing Information, Desyrel (trazodone hydrochloride), Apotex/various, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018207s032lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = ~65% (oral)<ref name="trazodone-label" />
	~~\| pregnancy~~ =		\| pregnancy = Limited human data; observational signals inconclusive.{{citation needed}}
	~~\| legal~~ =		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults<ref name="trazodone-label" />
	\| ~~intro =~~		\| mechanism = <vote slug="trazodone-mech-claim">Combined strong 5-HT2A antagonism with weaker serotonin reuptake inhibition (the SARI class signature). At the low doses used for insomnia (25-100 mg), 5-HT2A antagonism, H1 antihistaminergic effect, and α1-adrenergic antagonism dominate, producing sedation; at antidepressant doses (≥150 mg) the SRI contribution adds. The active metabolite mCPP is a 5-HT2C agonist that may contribute to anxiogenesis in some patients.</vote> '''Priapism''' is a recognized rare adverse effect via α1 antagonism in penile vasculature and is the marquee counseling point for male patients<ref name="trazodone-label" />.
	~~\| pharmacokinetics~~ =
	~~\| pharmacodynamics~~ =
	\| ~~indications~~ =
	\| ~~dosing~~ =
	\| ~~effects~~ =
	\| ~~interactions~~ = <~~pharmaInteractions~~/>
	~~\| pregnancy_details =~~
	~~\| monitoring =~~
	\| counseling =
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

			== References ==
			<references />

			[[Category:SARIs]]
	[[Category:Antidepressants]]		[[Category:Antidepressants]]
	[[Category:~~Serotonin Antagonist and Reuptake Inhibitors (SARIs)~~]]		[[Category:Sleep aids]]

MDElliottMD: Comprehensive categorization: +Serotonin Antagonist and Reuptake Inhibitors (SARIs)

2026-05-15T18:42:07Z

Comprehensive categorization: +Serotonin Antagonist and Reuptake Inhibitors (SARIs)

← Older revision		Revision as of 18:42, 15 May 2026
Line 32:		Line 32:

	[[Category:Antidepressants]]		[[Category:Antidepressants]]
			[[Category:Serotonin Antagonist and Reuptake Inhibitors (SARIs)]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:31:12Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:31, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:52Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:38Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Antidepressants]]		[[Category:Antidepressants]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Trazodone
+| generic            = Trazodone
-| brand             = Desyrel
+| brand              = Desyrel
-| classes           = SARI, Antidepressant, Sedative-Hypnotic
+| structure          =
-| mechanism         = Serotonin reuptake inhibitor and 5-HT2A antagonist
+| classes            = SARI, Antidepressant, Sedative-Hypnotic
 }}
 [[Category:Antidepressants]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Trazodone
| brand = Desyrel
| classes = SARI, Antidepressant, Sedative-Hypnotic
| mechanism = Serotonin reuptake inhibitor and 5-HT2A antagonist
}}
[[Category:Antidepressants]]